转移性激素受体阳性、HER2 阴性乳腺癌治疗途径的选择：优化二线内分泌和靶向治疗。

1

J Clin Oncol. 2024 Dec;42(34):4012-4017. doi: 10.1200/JCO-24-01295. Epub 2024 Sep 18.

2

J Clin Oncol. 2021 Dec 10;39(35):3890-3896. doi: 10.1200/JCO.21.01910. Epub 2021 Oct 28.

3

Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.

4

J Clin Oncol. 2020 Apr 20;38(12):1258-1267. doi: 10.1200/JCO.19.02242. Epub 2019 Oct 16.

5

Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24.

6

Curr Med Res Opin. 2014 Aug;30(8):1537-45. doi: 10.1185/03007995.2014.908829. Epub 2014 Apr 14.

7

J Clin Oncol. 2023 Aug 20;41(24):3976-3983. doi: 10.1200/JCO.23.00759. Epub 2023 Jul 5.

8

Curr Oncol. 2018 Jun;25(Suppl 1):S131-S141. doi: 10.3747/co.25.4000. Epub 2018 Jun 13.

9

J Clin Oncol. 2017 Sep 1;35(25):2866-2870. doi: 10.1200/JCO.2017.73.9482. Epub 2017 Jun 3.

10

J Clin Oncol. 2017 Aug 10;35(23):2600-2603. doi: 10.1200/JCO.2017.72.5960. Epub 2017 Jun 29.

Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies.